Cancer genomics, targeted therapy to precision oncology: the treatment paradigm is a holistic approach to cancer therapeutics
summary
The gist
Cancer genomics, targeted therapy to precision oncology: the treatment paradigm is a holistic approach to cancer therapeutics…
In short
Precision oncology uses multi-omics data combined with artificial intelligence and network biology to create personalized cancer treatments. This holistic approach analyzes complex molecular changes, such as mutations and signaling alterations, to tailor therapies for individual tumors.
Key concepts
- Precision Oncology
- This is a cancer therapy focused on genetically and molecularly profiling tumors to find specific alterations that drive cancer. It moves away from one-size-fits-all treatments by recognizing that patients with the same cancer can respond differently due to unique tumor DNA, RNA, and proteins.
- Multiomics Data Integration
- This involves combining different types of molecular data—like genomics, transcriptomics, and proteomics—from a single sample. Integrating these layers reveals complex molecular changes that are too subtle to see when looking at just one type of data alone.
- Tumor Heterogeneity
- Cancer tumors are not uniform; they contain many different cell types and genetic profiles within the same patient's tumor. Single-cell multiomics helps map these differences, showing how structural changes lead to varied biological processes in carcinogenesis.
- Network Biology AI
- This uses artificial intelligence and network models, like those based on protein interaction maps, to analyze complex biological data. It helps predict how different genetic mutations converge on key signaling pathways that drive cancer progression and can help identify new drug targets.
Terminology used across episodes
This episode discusses
- Cancer genomics, targeted therapy to precision oncology: the treatment paradigm is a holistic approach to cancer therapeutics · Paper Radio
The paper
Cancer genomics, targeted therapy to precision oncology: the treatment paradigm is a holistic approach to cancer therapeutics · Read on arXiv
Vellore Institute of Technology
Cancer is a fatal genetic disease involving unregulated cell growth and proliferation. Cellular behaviors such as growth, proliferation, survival, or death rely upon the ability of cells to communicate with the surrounding system; therefore, effective targeting of dysregulated signaling pathways involving growth factors, regulatory proteins, cell adhesion molecules, and immune system molecules is critical to cancer therapy. They are mainly driven by alterations in tumor suppressor genes and oncogenes that may vary among different cancer types. Importantly, patients with the same cancer type respond differently to available cancer treatments, likely due to tumor-specific DNA, RNA, and proteins, indicating the need for patient-specific treatment options. Precision oncology has evolved as a form of cancer therapy focused on genetic and molecular profiling of tumors to identify specific molecular alterations involved in carcinogenesis for tailored individualized cancer treatment. This article aims to briefly explain the foundations and frontiers of precision oncology, highlighting the cutting-edge innovations in tools and techniques associated with it to assess its scope and importance in achieving efficacious cancer treatment over time.
DOI: 10.7910/DVN/PUMKXM
Transcript
Introduction to the show: ident: Genomics Radio. Generated commentary on the latest computational biology and genomics papers.
Ines: I'm Ines.
Marcus: And I'm Marcus, here with Yuki.
Ines: We're looking at the paper: "Cancer genomics, targeted therapy to precision oncology".
Marcus: Here's the gist of the paper. Cancer genomics, targeted therapy to precision oncology: the treatment paradigm is a holistic approach to cancer therapeutics; this paper discusses how integrating multi-omics data with artificial intelligence and network biology is revolutionizing precision oncology by enabling personalized, tailored cancer treatments Foundations of Precision Oncology Precision oncology has evolved as a form of cancer therapy that is focused on genetic and molecular profiling of tumors to identify specific molecular alterations involved in carcinogenesis for tailored individualized cancer treatment The need for patient-specific treatment options arises because patients with the same cancer type respond differently to available treatments, likely due to tumor-specific DNA, RNA, and proteins Advances in high-throughput sequencing technologies have enabled gene expression profiling, providing multiomics data for detailed molecular characterization of various tumors Integration and analysis of various multiomic sequencing data are crucial in this regard, as they can reveal critical molecular changes, such as cancer-driving mutations, post-translational modifications, gene fusions, amplifications, and alterations in signaling networks within tumors Furthermore, the role of computational techniques such as artificial intelligence and deep learning is well established in precision medicine for analyzing complex data and identifying patterns of disease development for better outcomes Signaling Pathway Deregulation Cancer growth and progression are dependent on complex interactions between tumor cells, surrounding stromal cells and the ECM present in the TME The root cause underlying cancer progression remains genetic and epigenetic alterations linked to the regulation of cell growth and proliferation, cell adhesion, immune suppression, cell death, differentiation, and overall genomic stability of the affected cells Cancer cell signaling typically involves altered expression of the components of the signaling network which include many secreted protein receptors, growth factors and cytokines Cell division is regulated mainly by a group of extracellular growth factors that signal that resting cells divide by exploiting their intrinsic regulatory processes RTKs, such as EGFR, IGFR, PDGFR, FGFR, VEGFR, HGFR, or GPCR can activate the mitogen-activated protein kinase (MAPK) cascade Targeted cancer therapy targets specific genes and proteins involved in cancer cell reprogramming and signaling molecules to achieve effective treatment Integration of Multiomics and AI Multiomics refers to the approach where datasets of different omics groups are combined during sample analysis to allow scientists to read the more complex and transient molecular changes that underpin the course of disease progression and response to treatment The combination of big data, bioinformatics, and artificial intelligence is thought to lead to notable advances in translational research in cancer Deep learning uses artificial neural networks modeled on the human brain to emulate human understanding to obtain perfect solutions by processing unstructured data such as documents, images, and text AlphaFold 2 has revolutionized research by simplifying the accurate prediction of 3D structures of proteins PocketMiner uses graph neural networks to find hidden areas or pocket formations from a single protein, suggesting that approximately half of the proteins previously considered undruggable might have cryptic pockets that could be targeted successfully by anticancer agents Tumor Heterogeneity and Modeling Tumor heterogeneity is a hallmark property of cancer development and broadly refers to the differences between tumors of the same type in different patients, the differences between a primary and a secondary tumor, and the differences in genomic and phenotypic profiles displayed by cells within a single tumor Single-cell multiomics now facilitates the simultaneous measurement of thousands of genes and proteins in thousands of ‘single’ cells from a single sample to reveal how structural changes in chromosomes can lead to the complex biological processes involved in carcinogenesis Spatial biology combines whole-slide imaging (WSI) at single-cell resolution to visualize and quantify biomarker expression and reveal how cells interact and organize across the entire tissue landscape Engineering Relevant Models Two-dimensional cell culture models fail to accurately reproduce the complex architecture and biological dynamics of tumors in vivo, suffering from an insufficient understanding of cell-cell and cell-matrix interactions Three-dimensional in vitro tumor models, tumor organoids, have been developed to reproduce controlled microenvironments to study tumor biology and predict drug responses These 3D cancer models represent an ideal platform for the early screening of potential drugs for effective personalized therapies Recent advances in cancer genomics, AI-based technologies and single-cell multiomics have made targeted therapy the accepted form of cancer treatment The socioeconomic burden of cancer remains high, which is an indication for a renewed approach to expedite drug development to bring effective anticancer agents from the bench to the bedside in a cost-effective manner The use of molecular characterization of different cancer types through cancer genomics can help resolve drug-related issues by repurposing certain existing drugs as anticancer agents for a wide range of applications Continued research in this area holds the opportunity for improving cancer diagnosis, prevention, and treatment The move from tissue-based cancer-specific treatments to genome-based targeted treatments entails the reuse of anticancer drugs prescribed for one type of cancer to treat other cancer types as well Acknowledgements I would like to acknowledge the continued support from the School of Bio Sciences & Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India which enabled this work to be completed on time The funding information is not applicable The authors' contributions are not applicable There is no informed consent statement provided References The references listed in the paper support the claims made throughout the text, providing a foundation for understanding cancer genomics and precision oncology The references cover topics ranging from cancer burden patterns to specific molecular targets like protein kinase inhibitors and advanced single-cell sequencing techniques The comprehensive list of references indicates the breadth of literature supporting the holistic approach discussed in this paper The work synthesizes genomic, epigenetic, and spatial multi-omics to advance personalized cancer treatment strategies The focus on AI and deep learning for drug design prediction is a key theme in the current research landscape The paper emphasizes the necessity of integrating various data types to overcome the limitations of single-focus approaches in cancer research The framework for analyzing genome sequencing data to predict cancer evolution is a proposed method for systematic identification of driver networks The Cancer Cell Mapping Initiative aims to generate complete maps of major protein-based genetic interactions underlying cancer progression The Broad Institute's DepMap initiative focuses on screening thousands of cancer cell lines via RNA interference and CRISPR-Cas9 loss-of-function gene-editing strategies The integration of spatial multi-omics techniques is crucial for understanding the spatial arrangement of cells and their interactions in the native tissue environment The paper concludes that a wide range of people with cancer will benefit from this new development in cancer research in the future The authors acknowledge the support from their institution for completing this work on time The paper is supported by numerous references detailing the molecular mechanisms of cancer progression and therapeutic targets The entire study underscores the shift towards a personalized medicine approach in medical oncology The paper highlights the potential of novel computational methods to identify previously undruggable protein pockets The development of patient-derived tumor organoids is presented as an ideal platform for preclinical drug evaluation and dosage assessment The paper stresses the importance of understanding cell signaling networks to design effective therapeutic interventions that overcome resistance The holistic approach integrates genetics, epigenetics, multiomics, AI, and network biology for comprehensive cancer management The paper is a significant contribution to the field of precision oncology by outlining current frontiers and future directions The work provides a roadmap for leveraging big data in cancer analysis to achieve better diagnostic and prognostic outcomes The paper is a call for increased investment in research to bring effective anticancer agents from the bench to the bedside cost-effectively The study emphasizes that understanding genetic heterogeneity is key to finding efficacious agents for cancer treatment The paper advocates for a paradigm shift towards genome-based targeted treatments in oncology The work provides a detailed look at the application of next-generation sequencing and single-cell technologies in cancer research The paper is a resource for interpreting the cancer genome by identifying key complexes and pathways to be studied in greater mechanistic detail The work demonstrates how computational methods can predict drug response and synergy using deep learning models of human cancer cells The paper is a holistic approach to cancer therapeutics by combining multiple molecular layers for comprehensive understanding The paper serves as a guide for future research directions in precision oncology and personalized treatment strategies The work is an essential resource for translating complex multi-omics data into actionable clinical insights Page 36 --- The Cancer Genome Atlas (TCGA) Program is the landmark cancer genomics program supported by the NIH, which has contributed immensely to realizing the importance of genomics in cancer research and treatment in the last decade and has begun to change the way the disease has been treated in the clinic The National Cancer Institute (NCI), a leading cancer research enterprise, is part of NIH and is committed to exploiting basic cancer research for efficacious cancer therapies The Cancer Genome Atlas Research Network has profiled and analyzed a large number of human tumors to discover molecular aberrations at the DNA, RNA, protein and epigenetic levels and provided reliable diagnostic, prognostic and therapeutic markers for different types of cancer The Pan-Cancer Atlas has provided the most comprehensive and in-depth understanding of how and why tumors frequently arise in humans by analyzing over tens of thousands of tumors from the most prevalent forms of cancer Page 37 --- The PanCancer Atlas initiative appears to be a natural outcome of the TGCA program dedicated to comprehensive analysis of tumors on the basis of genomic studies to reveal alterations in signaling pathways, patterns of vulnerability and identify prospective targets for the development of precise drug treatments The synchronized view of oncogenic processes based on PanCancer Atlas analyses aims to elucidate the possible consequences of genome alterations on the different signaling pathways involved with human cancers, also reflecting their influence on the tumor microenvironment and immune cell responses to provide new insights into the development of new forms of targeted drugs and immunotherapies The stemness features extracted from transcriptomic and epigenetic data from TCGA tumors also present novel biological and clinical insight for cancer stem cell-targeted therapies Page 38 --- The Cancer Cell Mapping Initiative (CCMI) is a major development in cancer research dedicated to generating complete maps of major protein-based genetic interactions underlying cancer progression and attempting to develop computational methods using these maps to identify novel drug targets The CCMI is based on the NeST map, which relies on an integrated protein network created by combining interaction evidence from major data types such as protein‒protein interactions, mRNA coexpression, and sequence similarity The NeST map presented a total of 395 protein systems frequently involved in one or more types of cancer and therefore constitutes a resource on the cancer mechanisms for somatic mutations under consideration Page 39 --- The Cancer Cell Mapping Initiative aims to embark on a new era of cancer research and treatment on the basis of the complete elucidation of the molecular networks underlying different cancers The CCMI is an application of network biology that utilizes mathematical models to represent, integrate and analyse biological data through networks allowing the study of the properties of a complex system based on interactions between its individual constituents The CCMI is programmed to integrate computational methods and biological sciences to advance our understanding of the cellular functions underlying cancer progression and metastasis Page 40 --- The emerging field of single-cell technology thus provides unprecedented insight into the complex genetic and epigenetic heterogeneity within individual tumors for advanced precision oncology-based treatment Spatial multi-omics involves spatial mono-omics such as spatial genomics, transcriptomics, proteomics, epigenomics, metabolomics, etc.
Title and authors: Ines: Let's go over the title and authors of this paper again. "Cancer genomics, targeted therapy to precision oncology: the treatment paradigm is a holistic approach to cancer therapeutics". It sets up this idea that we need more than just genomic data; we need a whole system view for treating cancer.
Marcus: And the authors are Manish Kumar from the School of Bio Sciences and Technology at Vellore Institute of Technology, along with their team. They’re bringing together sequence analysis and genomics data science to tackle this big problem.
Yuki: When you think about "holistic approach," I think it implies that we can't just treat one part of the cancer mechanism in isolation; we have to see the whole picture from genetics to the tissue environment.
Ines: That’s what they’re getting at. They are arguing that precision oncology needs this holistic view, using multi-omics data and AI, to truly tailor treatments because patients with the same cancer can react totally differently.
Marcus: And they're pointing out that advances in high-throughput sequencing have given us enough data now to do this detailed molecular characterization of various tumors.
Yuki: It sounds like they are showing how combining big data from different omics groups—like gene expression, DNA, and protein changes—is the key to finding those critical molecular changes driving the disease.
The paper's summary: Ines: So, what’s the actual summary here? They’re saying that integrating these multiomic sequencing data is crucial because it reveals things like cancer-driving mutations, post-translational modifications, gene fusions, amplifications and alterations in signaling networks.
Marcus: That means they aren't just looking for a single mutation anymore; they are mapping out all the complex changes happening at the same time across different molecular layers. It’s about seeing the full molecular story.
Yuki: From a population perspective, I see this as trying to understand how these complex changes lead to the diverse clinical responses we see in patients with cancer. The summary highlights that precision oncology evolved by focusing on genetic and molecular profiling for individualized treatment options.
Ines: And they emphasize the role of computational techniques like AI and deep learning in analyzing this complex data to find patterns of disease development, which helps us get better outcomes.
Marcus: They mention specific tools, like AlphaFold two predicting protein structures or PocketMiner using graph neural networks to find cryptic pockets that might be druggable <ref:2304.05411#pg1>. That’s the engineering side of it, looking for new targets.
Yuki: That focus on finding those novel targets through computational prediction is important because it expands the possibilities beyond just targeting known mutations.
The paper's improvements: Ines: Now, let’s talk about what the paper suggests as improvements to this approach. They are proposing that we need to push AI systems further by integrating multiomics data analysis with artificial intelligence to analyze biological data through networks.
Marcus: That integration should allow the AI to identify those critical molecular changes they mentioned earlier—like cancer-driving mutations, post-translational modifications, gene fusions, amplifications and alterations in signaling networks within tumors.
Yuki: And when you look at population genetics, this means we can use network biology AI systems programmed with models like the Cancer Cell Mapping Initiative's NeST map to analyze how different genetic mutations converge on a few hallmarks signaling pathways responsible for cancer development.
Ines: That helps predict cancer evolution and associated clinical phenotypes because it explains how different genetic mutations in different patients have the same downstream effects on protein networks.
Marcus: They also suggest using machine learning algorithms to mine large datasets from multiomics platforms, imaging techniques, and biomarkers found by artificial intelligence to diagnose cancer early at its onset and help direct treatment options for individualized cancer therapy.
Yuki: That moves us toward a real diagnostic tool, not just a research tool. It’s about using these large datasets to predict outcomes before we even have the tumor fully characterized in every single patient.
Conclusion: Ines: So, to wrap up this discussion on "Cancer genomics, targeted therapy to precision oncology: the treatment paradigm is a holistic approach to cancer therapeutics", the paper stresses that this integrated view is how we achieve truly personalized cancer treatment.
Marcus: The implication for me as a data scientist is that we need better ways to handle batch effects and ensure our large cohorts are being analyzed in a way that captures these complex, multiomic interactions effectively.
Yuki: For population genetics, the big idea here is that by understanding this holistic approach, we can better understand the underlying drivers of cancer across different genetic backgrounds. It gives us a stronger framework to study how these diseases evolve and spread in humans.
Ines: I think the key point is moving from tissue-based treatments to genome-based targeted treatments, which involves reusing anticancer drugs prescribed for one type of cancer to treat other types as well.
Marcus: That’s a big idea for drug development efficiency, using existing agents across a wider range of applications based on molecular characterization.
Yuki: I just think it opens the door for understanding how different patient groups will respond to these new tailored treatments, which is crucial for real-world clinical application.
Ines: So that’s what we’re taking away from this paper on "Cancer genomics, targeted therapy to precision oncology: the treatment paradigm is a holistic approach to cancer therapeutics". We need that combined analysis of genomics and AI and network biology.
More episodes
- 2610.33881-Sensorimotor behavior from an untrained brain-and-nerve-cord connectome
- 2610.40344-Morphological Features of Murine Pulmonary Arterial Networks for Diagnosing Vascular Disease
- Daily Summary for 2026-11-19
- 2609.10193-Are You Learning Biological Signal or Shortcuts? Auditing and Mitigating Bias in Protein-Protein Interaction Datasets
- 2610.38236-Generative discovery of chemical reaction networks
- 2507.11176-An Interpretable AI framework Quantifying Traditional Chinese Medicine Principles Towards Enhancing and Integrating with Modern Biomedicine
- The day in conversation for 2026-11-19
- Daily Summary for 2026-11-19
- 2504.03590-Towards a Unified Framework for Determining Conformational Ensembles of Disordered Proteins
- 2603.15217-A multiscale discrete-to-continuum framework for structured population models